Last Updated on December 31, 2023 by The Health Master
Zydus Lifesciences’s subsidiary Zydus Worldwide DMCC has received tentative approval from the US Food and Drug Administration (USFDA) to market Selexipag tablets in the strengths of 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg and 1,600 mcg, the company said in a statement.
Selexipag is used in adults to treat Pulmonary Arterial Hypertension (PAH) to delay disease progression and reduce the risk of hospitalisation for PAH.
It is a prostacyclin receptor agonist. The drug will be manufactured at group’s formulation facility at SEZ, Ahmedabad, the statement added.
USFDA gives approval to Lupin Pregabalin capsules
USFDA gives final approval to Aleor Dermaceuticals for Docosanol cream
USFDA gives nod to these companies for Bortezomib for injection
USFDA grants approval for drug to treat spondylitis
USFDA approves this oral heart disease drug
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
USFDA gives approval to Lupin Pregabalin capsules
Global drug development centre set up for APIs and Formulations
New molecule discovered that can be used for treatment of diabetes
USFDA gives final approval to Aleor Dermaceuticals for Docosanol cream
Pharma Sector: “Act as if every day is an Audit”
USFDA gives nod to these companies for Bortezomib for injection
Israel opens world’s most protected Blood Bank
USFDA grants approval for drug to treat spondylitis
A smarter way to develop new drugs
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
